| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698234 | Clinical Oncology | 2014 | 7 Pages |
Abstract
A combined HDR boost and hypofractionated EBRT regimen offers a well-tolerated method of dose escalation with acceptable levels of patient-reported toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Choudhury, C. Arthur, J. Malik, P. Mandall, C. Taylor, N. Alam, A. Tran, J. Livsey, T. Elliott, S. Davidson, J.P. Logue, J. Wylie,